Big Rock Partners Acquisition News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.11.24	NRx Pharmaceuticals Names Michael Abrams CFO (RTTNews)
03.10.24	HOPE Therapeutics Says Intends To Acquire A Premier West Coast Interventional Psychiatric Clinic (RTTNews)
26.08.24	HOPE Therapeutics Announces $30 Mln Term Sheet From Lender - Quick Facts (RTTNews)
29.07.24	NRx Pharma, HOPE Therapeutics Align With FDA On Pediatric Study Plan For NRX-100 (RTTNews)
06.05.24	NRx Pharmaceuticals Plans To Seek Accelerated Approval Of NRX-101 - Quick Facts (RTTNews)
17.04.24	NRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal Flora (RTTNews)
08.04.24	NRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study (RTTNews)
01.03.24	NRx Pharmaceuticals Receives Approx. $1.0 Mln From Existing Investor - Quick Facts (RTTNews)
27.02.24	NRx Pharma Announces Pricing Of $1.5 Mln Share Offering, Stock Falls 32% (RTTNews)
12.02.24	NRx Pharmaaeuticals To Receive First $5 Mln Milestone Payment From Partners Alvogen And Lotus Pharma (RTTNews)
05.02.24	NRx Pharmaceuticals Incorporates HOPE Therapeutics; To Be Listed (RTTNews)
16.01.24	FDA Grants QIDP, Fast Track Designation To NRx Pharma's NRX-101 To Treat CUTI And Pyelonephritis (RTTNews)
02.01.24	NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco (PR Newswire)
02.01.24	NRx Pharmaceuticals (Nasdaq: NRXP) Demonstrates Compliance with Nasdaq MVLS Standard (PR Newswire)
27.12.23	NRx Pharmaceuticals Announces the Election of Janet Rehnquist to its Board of Directors (PR Newswire)
19.12.23	NRx Pharma Gains Rights To Data From Columbia University Supporting Use Of IV Ketamine (RTTNews)
19.12.23	NRx Pharmaceuticals Announces Signing of a Data and Technical Information Agreement with Columbia University Accessing Key Data Demonstrating Efficacy and Safety of Intravenous Ketamine for the Tr... (PR Newswire)
18.12.23	FDA OKs NRx Pharma's NDA For NRX-101 To Treat Complicated Urinary Tract Infections (RTTNews)
18.12.23	NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections (PR Newswire)
13.12.23	NRx Pharmaceuticals Provides Notice of Annual Meeting of Shareholders (PR Newswire)
11.12.23	NRx Pharmaceuticals to Participate in LifeSci Corporate Access Event (PR Newswire)
27.11.23	NRx Pharmaceuticals to Present at Noble Capital Markets' 19th Annual Emerging Growth Investor Conference (PR Newswire)
14.11.23	NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
07.11.23	NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023 (PR Newswire)
06.11.23	NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression (PR Newswire)
31.10.23	NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression (PR Newswire)
26.10.23	NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain (PR Newswire)
12.10.23	NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference (PR Newswire)
05.10.23	NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference (PR Newswire)
02.10.23	NRx Pharma Says FDA Grants Permission To Proceed On IND For NRX-101 To Treat Chronic Pain (RTTNews)
02.10.23	NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain (PR Newswire)
20.09.23	NRx Pharmaceuticals Publishes Shareholder Update Letter (PR Newswire)
18.09.23	NRx Pharmaceuticals to Present at the Sidoti Virtual Small Cap Conference (PR Newswire)
15.09.23	NRx Pharma Signs Data Sharing Agreement Related To Patients With Suicidal Bipolar Depression (RTTNews)
15.09.23	NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression (PR Newswire)
14.09.23	NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support (PR Newswire)
07.09.23	NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
06.09.23	NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens (PR Newswire)
30.08.23	NRx Pharma Submits IND Application For NRX-101 To Treat Chronic Pain - Quick Facts (RTTNews)
30.08.23	NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain (PR Newswire)
29.08.23	NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share (PR Newswire)
14.08.23	NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
07.08.23	NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023 (PR Newswire)
07.08.23	NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain (PR Newswire)
20.06.23	NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference (PR Newswire)
09.06.23	NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering (PR Newswire)
06.06.23	NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering (PR Newswire)
02.06.23	NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023 (PR Newswire)
16.05.23	NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
10.05.23	NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Big Rock Partners Acquisition Corp Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten